Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioAge Labs, Inc. before investing.

In this article, we go over a few key elements for understanding BioAge Labs, Inc.’s stock price such as:

• BioAge Labs, Inc.’s current stock price and volume
• Why BioAge Labs, Inc.’s stock price changed recently
• Upgrades and downgrades for BIOA from analysts
• BIOA’s stock price momentum as measured by its relative strength

About BioAge Labs, Inc. (BIOA)

Before we jump into BioAge Labs, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Want to learn more about BioAge Labs, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioAge Labs, Inc..

BioAge Labs, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, BioAge Labs, Inc.’s stock price was $9.040.

BioAge Labs, Inc. is down 63.62% from its previous closing price of $24.850.

During the last market session, BioAge Labs, Inc.’s stock traded between $8.650 and $10.810. Currently, there are approximately 42.48 million shares outstanding for BioAge Labs, Inc..

BioAge Labs, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

BioAge Labs, Inc. Stock Price History

BioAge Labs, Inc.’s (BIOA) price is currently down 63.12% so far this month.

During the month of July, BioAge Labs, Inc.’s stock price has reached a high of $25.950 and a low of $8.650.

Over the last year, BioAge Labs, Inc. has hit prices as high as $25.955 and as low as $4.110. Year to date, BioAge Labs, Inc.’s stock is down 31.67%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BioAge Labs, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded BioAge Labs, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BioAge Labs, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioAge Labs, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BioAge Labs, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioAge Labs, Inc. (BIOA) by visiting AAII Stock Evaluator.

Relative Price Strength of BioAge Labs, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, BioAge Labs, Inc. has a weighted four-quarter relative price strength of 55.13%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how BioAge Labs, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioAge Labs, Inc. Stock Price: Bottom Line

As of July 31, 2026, BioAge Labs, Inc.’s stock price is $9.040, which is down 63.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioAge Labs, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.